Nautilus debuted its platform at the US HUPO meeting last month and is seeking additional participants for its ongoing early ...

The integration of high-throughput proteomics into modern cancer research has fundamentally altered the landscape of oncological profiling and therapeutic development. While genomic and transcriptomic ...

IMAC Holdings, Inc. has launched Ignite Proteomics LLC, a new subsidiary focused on enhancing cancer treatment personalization through protein-level analysis. This initiative aims to improve the ...

Ignite Proteomics LLC announced the publication of a pivotal study in the British Journal of Cancer, which emphasizes the importance of measuring activated proteins in the AKT–mTOR signaling pathway ...

The Cancer Prevention and Research Institute of Texas is supporting a Cancer Proteomic and Metabolomic Core Facility that provides consultation, instrumentation, technical support and data analysis ...

Acute myeloid leukemia (AML) remains one of the most difficult blood cancers to treat. Although drug combinations are often ...

SAMBAI, a team funded through the Cancer Grand Challenges initiative, reported that Akoya Biosciences’ PhenoCycler ®-Fusion system will be the foundational spatial proteomics technology used to ...

When Matthew Padula was diagnosed with a rare bladder cancer in 2020, he knew there was a challenging road ahead of him. As a researcher at the University of Technology Sydney, his first instinct was ...

Nashville, TN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (BACK) (“IMAC Holdings” or the “Company”) has launched Ignite Proteomics LLC (“Ignite”), its new subsidiary dedicated to helping ...

Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc ...